This is a working overview of incretin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
=== Western Balkans === Since the beginning of the 21st century, the global drug trade network has witnessed the emergence of criminal groups from the Western Balkans as crucial players. These groups have moved up from being small-time crooks to major drug distributors. Most of these organized crime groups originated in Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia. The illicit trade activities of the Balkans primarily involved Latin America, Western Europe, South Africa, Australia and Turkey. These groups keep their operations outside the Western Balkans, while staying connected to their homeland. Within the network of these groups, the dealmakers operate near supply sources and the distribution networks are managed by foot soldiers. However, the bosses of the organized criminal groups stay and keep their wealth in the United Arab Emirates (UAE). The UAE is amongst the enablers of global corruption and illicit financial flows. Analysts have claimed that criminal actors across the world either operate from or through the UAE. It was a haven for criminals, where the risk from conducting illicit activities remains low. For the Balkan criminals, a growing trend was to relocate to the UAE, which became attractive to "dirty money" and kingpins from several European nations and the United Kingdom. Besides, Dubai was also dubbed as the "new Costa del Crime", replacing the crime hideaway of Spain, the Costa del Sol. The UAE had poor regulations for money laundering and for screening of suspicious transactions.
== Principle of operation == The quadrupole consists of four parallel metal rods. Each opposing rod pair is connected together electrically, and a radio frequency (RF) voltage with a DC offset voltage is applied between one pair of rods and the other. Ions travel down the quadrupole between the rods. Only ions of a certain mass-to-charge ratio will reach the detector for a given ratio of voltages: other ions have unstable trajectories and will collide with the rods. This permits selection of an ion with a particular m/z or allows the operator to scan for a range of m/z-values by continuously varying the applied voltage. Mathematically this can be modeled with the help of the Mathieu differential equation.
=== Continuous and individualized delivery systems === As Parkinson's disease advances, the duration, efficacy and reliability of levodopa progressively decline producing unstable plasma concentration and motor fluctuations. The fluctuations contribute to a series of motor and non-motor complications including wearing off and levodopa induced dyskinesia that need a better tailored pharmaceutical approach to the disease. A steady activation of the dopaminergic receptors was initially pursued through intravenous infusion which shortly was replaced by a series of new levodopa device-aided formulations. Duodopa or Levodopa-carbidopa intestinal gel (LCIG) is a methylcellulose-based suspension of levodopa and carbidopa delivered in a continuous way into the duodenum or jejunum through a portable pump and a PEG-J tube system. In randomized studies, LCIG proved to reduce daily OFF time and increase ON time without troublesome dyskinesia but, at the same time, carries with it problems related to the infusion system, such as PEG-J and stoma complications. Produodopa is a soluble prodrug formulation of fosfolevodopa/foscarbidopa developed for a 24 hour subcutaneous infusion. After the infusion, the prodrug is converted by phosphatases into active levodopa and carbidopa that manage to stabilize their concentration in the blood. Compared with levodopa/carbidopa, the prodrug approach increases ON time without troublesome dyskinesia by 1.75 hours and reduced OFF time by 1.79 hours other than improvements also in quality of life, motor fluctuations and sleep.
Sources: en.wikipedia.org
=== Licensing status === The Orion Corporation originally developed levosimendan and applied for a new drug application in 1998 in the U.S. However the Food and Drug Administration (FDA) requested further trials be conducted and Orion withdrew the application in November 1999. Initially, Orion obtained the approval to market the drug in Sweden in 2000. Since then 60 countries worldwide have approved the drug for acute cardiac care, but it remains unapproved in North America, where it is currently in Phase III development by Tenax Therapeutics for reduction in morbidity in patients with Pulmonary Hypertension derived from Heart Failure with preserved Ejection Faction (PH-HFpEF).
=== Drug addiction === It has been found that cocaine produces a decrease in Cystine-Glutamate exchange via system Xc-, leading to a decrease in basal, extra synaptic glutamate levels in the nucleus accumbens core (NAcc) region of the brains of cocaine-withdrawn rats. It has also been observed in withdrawn rats that a decrease in Group 2 mGluR inhibition of vesicular release, most likely due to the decrease in extrasynaptic glutamate levels, leads to an increase in cocaine-evoked glutamate signaling in their NAcc. An infusion of cysteine in the NAcc of withdrawn rats leads to an increase in extrasynaptic glutamate, near the levels of the control rats, and prevents an increase in synaptic glutamate signaling after a cocaine injection. These findings suggest there is a decrease in system Xc- activity in cocaine-withdrawn rats. It has also been found that cocaine increases glutamate signaling in the synaptic cleft, further supporting this conclusion. Administration of the cysteine prodrugs N-acetylcysteine or L-2-oxothiazolidine-4-carboxylate blocks cocaine reinstatement in rats. N-acetylcysteine has been shown to decrease drug-seeking behavior for nicotine and heroin as well. However, N-acetylcysteine does not alter the cocaine-induced rush or euphoria; it only causes a reduction in drug-seeking behavior. N-acetylcysteine works by increasing levels of cysteine in cells, leading to an increase in system Xc- activity.
On 1 July 1972 at Villamanrique de la Condesa, near Seville, Spain, he married Princess Maria da Gloria of Orléans-Braganza (b. 1946) from the Brazilian imperial family, at the parish church of St. Mary Magdalene. They are double 4th cousins once removed as both are descendants of Prince Ferdinand of Saxe-Coburg and Gotha (1785–1851) and Princess Maria Antonia von Koháry (1797–1862), as well as of Pedro I, Emperor of Brazil and Archduchess Maria Leopoldina of Austria. They have three sons: Peter (born 5 February 1980), and fraternal twins: Philip and Alexander (both born 15 January 1982). Alexander and Maria da Gloria divorced on 19 February 1985. Both of them married for the second time. Maria da Gloria married Ignacio de Medina, Duke of Segorbe (b. 1947), while Crown Prince Alexander married Katherine Clairy Batis, daughter of Robert Batis and Anna Dosti, civilly on 20 September 1985, and religiously the following day, at St. Sava Serbian Orthodox Church, Notting Hill, London. Since their marriage, she is known as Crown Princess Katherine, as per the royal family's website. On 16 December 2017, Alexander attended with his wife the state funeral of his first cousin once removed, King Michael of Romania in Bucharest, along with other heads of European royal families and invited guests. On 19 September 2022, Crown Prince Alexander and his wife Katherine attended the state funeral of his godmother Queen Elizabeth II.
Sources: en.wikipedia.org
End of discussion." Sanders supports establishing worker-owned cooperatives and introduced legislation numerous times from the 1990s to the 2020s that would aid workers who want to "form their own businesses or to set up worker-owned cooperatives." As early as 1976, Sanders proposed workplace democracy, saying, "I believe that, in the long run, major industries in this state and nation should be publicly owned and controlled by the workers themselves." Likewise, he supports empowering and expanding labor unions to advance union democracy. In 1987, Sanders defined democracy as public ownership and workers' self-management in the workplace, saying: "Democracy means public ownership of the major means of production, it means decentralization, it means involving people in their work. Rather than having bosses and workers it means having democratic control over the factories and shops to as great a degree as you can." In his 2020 run for president, he proposed that 20% of stocks in corporations with over $100 million in annual revenue be owned by the corporation's workers and that 45% of the board of directors of corporations with over $100 million in annual revenue be elected by the workers of that corporation.
==== Protocells ==== Microcapsules termed protocells prepared by polymer-protein hybrids are the hotspot of the research area recently, enabling various functions such as bioreactors, cascade system and multiresponsive membranes, etc.
=== Thermoresponsivity in organic solvents === Due to the low entropy of mixing, miscibility gaps are often observed for polymer solutions. Many polymers are known that show UCST or LCST behavior in organic solvents. Examples for organic polymer solutions with UCST are polystyrene in cyclohexane, polyethylene in diphenylether or polymethylmethacrylate in acetonitrile. An LCST is observed for, e.g., polypropylene in n-hexane, polystyrene in butylacetate or polymethylmethacrylate in 2-propanone.
We are the new group Mata Zetas (Zeta Killers) and we are against kidnapping and extortion, and we will fight them in all states for a cleaner Mexico. These murdered men were then linked to individuals who had been shown in a video on YouTube while being interviewed by masked men armed with assault rifles. A number of videos online confirmed the existence of the Jalisco New Generation Cartel, which was dedicated at that time to kill Gulf Cartel and Zeta members alike. In the interrogation videos done by the Mata Zetas, the captured cartel members confessed their criminal activities and gave out the names of police commanders and politicians who provided them with protection. According to Terra Networks, the government agency of the SEIDO received a phone call on 1 July 2009 from an unidentified man who said that the cartel members of Los Zetas were going to be "kidnapped and eliminated" from Cancún and Veracruz.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。